Both PNPLA3 I148M and hepatic inflammation are associated with nonalcoholic fatty liver disease (NAFLD) progression. This study aimed to elucidate whether PNPLA3 I148M is involved in NF-kB-related inflammation regulation in NAFLD. HepG2 cells homozygous for the PNPLA3 I148M mutation were used. The human PNPLA3 promoter sequence was screened for NF-kB binding sites using the MATCH and PATCH tools. NF-kB-mediated transcriptional regulation of the PNPLA3 gene was assessed by luciferase reporter assay, EMSA and ChIP-qPCR. Wild-type (I148I) and mutant (M148M) PNPLA3 were overexpressed using stable lentivirus-mediated transfection. The pCMV vector and siRNA were transiently transfected into cells to direct NF-kB overexpression and PNPLA3 silencing, respectively. A putative NF-kB binding site in the human PNPLA3 promoter was shown to be necessary for basal and NF-kBdriven transcriptional activation of PNPLA3 and protein/DNA complex formation. Supershift analysis demonstrated a protein/DNA complex specifically containing the NF-kB p65 and p50 subunits. ChIP-qPCR confirmed the endogenous binding of NF-kB to the human PNPLA3 promoter in response to NF-kB overexpression and palmitic acid (PA) challenge. The silencing of PNPLA3 blocked the overexpression of NF-kB or PA-induced TNF-α up-regulation. Moreover, mutant PNPLA3 overexpression prevented NF-kB inhibitor-induced down-regulation of TNF-α expression in PA-treated HepG2 cells. Finally, the overexpression of mutant but not wild-type PNPLA3 increased TNF-α expression and activated the ER stress-mediated and NF-kB-independent inflammatory IRE-1α/JNK/c-Jun pathway. Human PNPLA3 was shown to be a target of NF-kB, and PNPLA3 I148M mediated the regulatory effect of NF-kB on inflammation in PA-treated HepG2 cells, most likely via the IRE-1α/JNK/c-Jun ER stress pathway. K E Y W O R D S ER stress, inflammation, NAFLD, NF-kB, PNPLA3
| INTRODUC TI ON
Nonalcoholic fatty liver disease (NAFLD) is a clinicopathological syndrome characterized by diffuse ballooning fatty degeneration of hepatocytes and fat storage and excludes effects caused by alcohol and other known harmful factors to the liver. 1 The histological spectrum of NAFLD ranges from simple steatosis to steatohepatitis, hepatic fibrosis, cirrhosis and even hepatocellular carcinoma. 1, 2 The histologic progression of NAFLD involves two steps of liver injury (the two-hit theory): The first hit is mainly intrahepatic fat accumulation caused by insulin resistance, and the second hit is mainly liver injury and steatohepatitis caused by inflammation. 3 Genome-wide association studies (GWAS) have shown that the PNPLA3 gene, which is mainly expressed in the liver and fat, is susceptible to NAFLD. 4 The function of the PNPLA3 gene remains unclear, although in vitro studies have shown that the PNPLA3 protein has triacylglycerol (TG) hydrolase, 5 lysophosphatidyl acyltransferase (LPAAT) 6 and calcium-independent phospholipase A2 (iPLA2) activities. 7 The PNPLA3 I148M (rs738409) polymorphism is associated with not only liver fat content but also hepatocyte steatohepatitis, fibrosis and cirrhosis, 8 suggesting that PNPLA3 I148M plays a key role in the progression of NAFLD. As the two-hit theory of NAFLD claims that inflammation contributes to the progression of NAFLD and more inflammatory infiltration and liver damage were found in NAFLD patients carrying PNPLA3 I148M than those carrying wild-type genotype, 9 we speculated that PNPLA3 I148M is closely related to liver inflammation. Furthermore, NF-kB is the most important transcription factor regulating inflammation and involved in the pathogenesis of NAFLD progression. 10 Therefore, we are very interested in the involvement of the PNPLA3 gene in NF-kB signalling, which links inflammatory responses in NAFLD. In this study, we show that PNPLA3 is a target gene regulated by NF-kB and that the PNPLA3 M148M protein participates in regulating the palmitic acid (PA)induced inflammatory response in HepG2 cells carrying a homozygous PNPLA3 148M genotype. These findings may provide a new means to elucidate the role of PNPLA3 I148M in NAFLD.
| ME THODS

| Cell culture and treatment
Human hepatocellular carcinoma (HepG2) cells obtained from cell bank of CAS were cultured in MEM/EBSS medium (SH30024.01B, Hyclone) supplemented with 10% foetal bovine serum (10099-141, Gibco). HepG2 cells at 60%-70% confluence were starved in serumfree medium overnight before treatment. To induce FFA overloading, the cells were treated with 500 mmol/L palmitic acid (PA, P5585, Sigma-Aldrich) for certain times. Control cells were incubated with the same medium containing the same amount of solvent (BSA) used to dissolve the PA. For treatment experiments, the cells were pretreated with 10 μmol/L PDCT (P8765, Sigma-Aldrich) for 6 hours before transfection or 10 μmol/L BAY11-7082 (B5556, Sigma-Aldrich) for 1 hour before PA treatment.
| Construction of plasmid vectors
To construct pGL3-WT luciferase reporter vector, the 542 nt fragment (−506 to +36) of human PNPLA3 gene containing putative binding sites for NF-kB was amplified by PCR using the following KpnI/MluI site-linked primers: sense 5′-ATGGTACCATCAAGTGGGCACCAACTG-3′ and antisense 5′-AT ACGCGT GAAGGACAAGCTCCAGCC-3′, and was cloned in the pGL3-Basic firefly luciferase reporter vector (Promega). 
| Transient transfection and Dual-luciferase reporter assay
The 
| SiRNA (small interfering RNA) transfection
Human PNPLA3 was knocked down using siRNA oligoribonucleotides targeting PNPLA3 (SiRNA-PNPLA3) with the following target sequences: GTGACAACGTACCCTTCAT. A non-targeting siRNA (SiRNA-Mock) (5′-UUCUCCGAACGUGUCACGU TT 3′) was used as a control.
HepG2 cells were treated with 2 μg siRNA using X-tremeGENE siRNA Transfection Reagent (04476493001, Roche) in a serum-free medium for 6 hours, and then, the medium was supplemented with serum and maintained in culture for 48 hours. Cells were then either lysed to use for Western blotting or were evaluated for mRNA expression.
| Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extracts were prepared from HepG2 cells using Nuclear Figure   S1A ). Dissolution curve of the primers is presented in Figure S1B .
| Chromatin immunoprecipitation (ChIP)-qPCR assay
| Isolation of total RNA extraction and analysis by qPCR
Total RNA was extracted from HepG2 cells using TRIzol reagent Table S2 .
| Statistical analysis
Data represent the mean ± standard deviation (SD) values of three independent duplicate experiments. Statistical analysis was performed using one-way ANOVA analysis of variance followed by Student's t test. A value of P < .05 was considered to be statistically significant.
| RE SULTS
| NF-kB is involved in regulating human PNPLA3 expression
To clarify the relationship between NF-kB and PNPLA3 expression, we detected the expression of PNPLA3 protein and mRNA in HepG2 cells transiently overexpressing NF-kB p65. As shown in Figure 1 , the protein ( Figure 1A is C), although DNA sequence alignment analysis showed this sequence was not conserved with mouse, rat and chicken ( Figure S3 ).
| Identification of a NF-kB binding site −357/−366 bp upstream of the translation start site of the human PNPLA3 gene
The pGL3-WT, PGL3-Mutant and pGL3-Basic reporter constructs were transiently transfected into HepG2 cells, and basal transcriptional activity was measured 24 hours after cotransfection by dual-luciferase reporter assay. As shown in Figure 2B , 
| PA-induced PNPLA3 expression was mediated by NF-kB
| NF-kB, rather than SREBP-1c, regulated PNPLA3 expression in long-term PA-treated HepG2 cells
Given that SREBP-1c is a known PNPLA3 target gene that can also be activated by PA, it is first necessary to clarify changes in SREBP-1c and NF-kB expression over time during PA intervention to avoid confounding effects of SREBP-1c. Expression of nucleoprotein NF-kB and SREBP-1c was detected before (0 hours) and after 6, 12
and 24 hours of PA treatment. As shown in Figure 4A As shown in Figure 4B Figure 4C ). This result suggested that long-term PA treatment increases the expression of PNPLA3 by NF-kB.
| PA increases the endogenous binding of NF-kB to the human PNPLA3 promoter
The endogenous interaction between NF-kB and the PNPLA3 pro 
| PNPLA3 mediated the inflammatory regulation by NF-kB in PA-treated HepG2 cells
To determine the role of PNPLA3 in NF-kB-mediated inflamma- 
| PNPLA3 M148M, but not wild-type PNPLA3, regulated TNF-α expression and activated the ER stress-associated IRE-1α/JNK/c-Jun pathway
As PNPLA3 I148M is a well-known risk genotype for NAFLD, while those with PNPLA3 I148I are protected from NAFLD, we sought to determine whether these two genotypes mediate different in- 
| D ISCUSS I ON
The PNPLA3 I148M is susceptible to NAFLD 4 and NAFLD progression, 8 with PA for 24 hours, PNPLA3 was transcriptionally regulated by NF-kB rather than SREBP-1c, and mutant PNPLA3 M148M, but not wild-type PNPLA3 I148I, was involved in PA-induced regulation of the inflammatory factor TNF-α. This study is the first to report the mechanism by which NF-kB regulates PNPLA3 and the role of PNPLA3 I148M in regulating inflammation in NAFLD.
Although PNPLA3 is the most studied gene susceptible to NAFLD, a functional study using knockout mice did not find any abnormal metabolic phenotype. 13, 14 Moreover, liver-specific PNPLA3 I148M overexpression 15 and I148M point mutation knock-in mice 16 exhibited significant susceptibility to liver fat deposition induced by a high-sucrose diet but did not show evidence of the promotion of NAFLD progression, such as nonalcoholic steatohepatitis (NASH) and hepatic fibrosis. Phenotypic differences between murine models and human patients suggested the limitations of murine models in studying PNPLA3. The different PNPLA3 protein sequence lengths and gene regulation between human and mouse have been shown; the human PNPLA3 protein is 97 amino acids longer than the murine PNPLA3 protein at the C-terminal end, which contains two-vesicle targeting motifs, 17 suggesting human-specific functions of PNPLA3. In addition, ChREBP, a lipogenic glucose-sensing transcription factor, was found to transcriptionally regulate PNPLA3 gene expression in mice and not humans. 18 In previously identified mouse and human sterol regulatory elements (SREs), 19, 20 in addi- cell line, which is widely used to study liver diseases, was found to carry homozygous PNPLA3 M148M genotype. 17 This characteristic makes HepG2 cells a natural mutation model in which to study the function of human PNPLA3 I148M and its role in NAFLD. Some researchers even consider HepG2 cells to be an ideal in vitro model for studying PNPLA3. 17 SREBP-1c is a transcription factor that regulates lipid synthesis and can also be activated by PA in vitro. Our previous study showed the direct transcriptional regulation of human PNPLA3 by SREBP-1c. 19 Therefore, in addition to the effect of NF-kB on PNPLA3 expression, the effect of SREBP-1c on PNPLA3 expression after PA treatment should be considered. In this study, the nuclear expression of SREBP-1c and NF-kB varied with PA treatment time.
The pattern of changes in SREBP-1c and NF-kB expression was consistent with a report from Nagaya et al 21 showing that inflammation persisted, and hepatic lipid deposition and SREBP-1c expression decreased as NASH progressed. Based on our results, 24 hours was chosen as the PA treatment time because the interaction between NF-kB and PNPLA3 was significant at this time, and nuclear SREBP-1c expression was close to its baseline level.
GWAS found that people carrying PNPLA3 I148M are susceptible to the presence and progression of NAFLD, 8 but the mechanism of this susceptibility is still unknown. Whether increased susceptibility is attribute to a functional gain due to increased LAPPT activity 6 or a functional deficiency due to inhibited TG lipase activity 5, 22 remains controversial. Additionally, the mechanism by which PNPLA3 I148M promotes NAFLD progression could not be explained by its LAPPT or TG lipase activities. This study in a PA-induced NAFLD HepG2 cell model is the first to report that PNPLA3 I148M is regulated by NF-kB and involved in the regulation of TNF-α expression.
TNF-α is a proinflammatory cytokine that contributes to the second hit in NASH pathogenesis. 23 Thus, our results provide new insight to elucidate the function of PNPLA3 I148M mutant protein and its role in NAFLD and explain why NAFLD patients carrying the PNPLA3 148M are more susceptible to progressive NAFLD.
The mechanism by which PNPLA3 regulates the inflammatory response is worth discussing. PNPLA3 has mild iPLA2 activity in vitro. 7 AA and lysophosphatidylcholine (LPC) produced from membrane phospholipids by the enzymatic action of iPLA2 are involved in modulating inflammation. Theoretically, PNPLA3 I148M therefore may regulate TNF-α expression due to an increase in PNPLA3mediated AA production. However, overexpression of wild-type and mutant PNPLA3 in HepG2 cells in our study or in transgenic mice did not alter the levels of AA, or hepatic AA-derived prostaglandins or LPC. 13 Thus, increased iPLA2 activity could not explain the increased proinflammatory effects of PNPLA3 I148M compared to those of wild-type PNPLA3. ER stress plays a crucial role in NASH progression. 24 Lipid droplets (LDs) originate from the ER and regulate ER stress. 25 In both HuH7 cells 26 and I148M mutation knock-in mice, 16 PNPLA3 I148M mutant protein, but not wild-type PNPLA3, was found to localize mainly in LDs. Therefore, the different distributions of LDs with the expression of wild-type and mutant PNPLA3 protein might explain why mutant proteins activated ER stress but wild-type proteins did not. As the overexpression of wild-type 
